Stoss M, van Wely M, Musielsky H, Gorter R W
European Institute for Oncological and Immunological Research, Berlin, Germany.
Arzneimittelforschung. 1999 Apr;49(4):366-73. doi: 10.1055/s-0031-1300428.
Subcutaneous injections of fermented and unfermented aqueous extracts of Viscum album L. result in a local inflammatory reaction at the injection site. In this trial, the symptoms associated with this local reaction were investigated. Furthermore the occurrence of local reactions was tried to correlate with an increase in CD3/25- and CD8/38-positive lymphocyte counts, with eosinophilic granulocyte numbers, and with the formation of mistletoe lectin antibodies. Included in the trial were 30 HIV-antibody-positive patients and 17 healthy non-smokers, aged 24-51 years. The CD4 cell count in the HIV-negative subjects was > 800/microliter, compared with 200-600/microliter in the HIV-positive patients. All study participants had a Karnofsky score > or = 70. The trial subjects were observed over a period of 18 weeks. With escalation of the dose of a fermented and unfermented extract of Viscum album L. (Iscador Qu Spezial and Viscum album QuFrF), there was an increase in local reactions. Erythema at the injection site was the most frequently reported symptom. Between the doses and the symptoms induration, swelling and pruritus were marked correlations. Effects of the application of mistletoe extracts on the immune system were demonstrated by an increase in CD3/25-positive lymphocyte counts and antibodies against mistletoe-lectins. There were no changes in eosinophilic granulocytes or CD8/38-positive lymphocyte populations. For evaluation of the therapeutic applications of mistletoe extracts in HIV-positive patients it is advisable to assess primarily activation of CD3-positive lymphocytes and the patient response on the basis of the local reaction. The local inflammatory reaction at the injection site is desirable and well tolerated if the reaction is smaller than 5 cm in diameter.
皮下注射槲寄生(Viscum album L.)的发酵和未发酵水提取物会在注射部位引发局部炎症反应。在本试验中,对与这种局部反应相关的症状进行了研究。此外,还试图将局部反应的发生与CD3/25和CD8/38阳性淋巴细胞计数的增加、嗜酸性粒细胞数量以及槲寄生凝集素抗体的形成联系起来。该试验纳入了30名HIV抗体阳性患者和17名年龄在24至51岁之间的健康非吸烟者。HIV阴性受试者的CD4细胞计数>800/微升,而HIV阳性患者的CD4细胞计数为200 - 600/微升。所有研究参与者的卡诺夫斯基评分≥70。对试验对象进行了为期18周的观察。随着槲寄生(Viscum album L.)发酵和未发酵提取物(Iscador Qu Spezial和Viscum album QuFrF)剂量的增加,局部反应也随之增加。注射部位的红斑是最常报告的症状。在剂量与硬结、肿胀和瘙痒等症状之间存在明显的相关性。槲寄生提取物应用对免疫系统的影响表现为CD3/25阳性淋巴细胞计数增加以及针对槲寄生凝集素的抗体增加。嗜酸性粒细胞或CD8/38阳性淋巴细胞群体没有变化。为了评估槲寄生提取物在HIV阳性患者中的治疗应用,建议主要评估CD3阳性淋巴细胞的激活情况以及基于局部反应的患者反应。如果注射部位的局部炎症反应直径小于5厘米,则是可取的且耐受性良好。